Blood filter attached to Heart-Lung machine aims to stop ticagrelor bleeding

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: 1. Patient or patient's representative having read and understood the information letter and signed the consent form 2. Age ≥ 18 y/o 3. Ticagrelor administration within 48 hours prior to surgery 4. Cardiac surgery with cardiac bypass 5. Patient affiliated with, or beneficiary of a social security (health insurance) category. 6. Women of childbearing potential (a woman is considered of childbearing potential (WOCBP), i.e. fertile, following menarche and until becoming post-menopausal unless permanently sterile): 1. with effective contraception (Cf. CTCG) (progestogen-only oral hormonal contraception, where inhibition of ovulation is not the primary mode of action, male or female condom with or without spermicide, cap, diaphragm or sponge with spermicide) since 1 month, during study period 2. negative blood pregnancy test by b-HCG at inclusion. 7. Women permanently sterile (hysterectomy, bilateral salpingectomy and bilateral oophorectomy) 8. Postmenopausal women: A postmenopausal state is defined as no menses for 12 months without an alternative medical cause. A high follicle stimulating hormone (FSH) level in the postmenopausal range may be used to confirm a post-menopausal state in women not using hormonal contraception or hormonal replacement therapy. However in the absence of 12 months of amenorrhea, a single FSH measurement is insufficient. Exclusion Criteria: 1. Concomitant antiplatelet drugs or ongoing anticoagulants other than aspirin and heparin 2. Ongoing systemic infection (including active endocarditis) 3. Ongoing treatment with an antibiotic or antifungal at high risk of removal by Cytosorb®: teicoplanin, vancomycin, linezolid, gentamycin, amphotericin B liposomal, azole drugs or fluconazole 4. Ongoing treatment with an anticonvulsant at high risk of removal by Cytosorb®: phenytoin, phenobarbital or valproic acid. 5. Contraindications to Cytosorb® (known preoperative platelet count \< 20 000/mm3, Sickle cell disease crisis, history to heparin-induced thrombopenia, body mass index ≥ 40 kg/m², hypersensitivity to a component, Any pre-existing contraindication to extracorporeal therapy (CPB)) 6. Cardiac surgery for ventricle assistance device or transplantation 7. Preoperative critical state 8. Chronic pathology with life expectancy less than 1 month 9. Pregnant or breastfeeding women and women of child-bearing age not using effective means of contraception 10. Absence of affiliation to a social security program 11. Person deprived of liberty by an administrative or judiciary decision or person placed under judicial protection, under guardianship or supervision 12. Person consenting to the research participating having participated to another trial within a period of one week 13. Person participating to another interventional research